To investigate, in patients with metastatic prostate cancer, whether radiomics of computed tomography (CT) image data enables the differentiation of bone metastases not visible on CT from unaffected bone using 68 Ga-PSMA PET imaging as reference standard.
In this IRB-approved retrospective study, 67 patients (mean age 71 ± 7 years; range: 55-84 years) showing a total of 205 68 Ga-PSMA-positive prostate cancer bone metastases in the thoraco-lumbar spine and pelvic bone being invisible in CT were included. Metastases and 86 68 Ga-PSMA-negative bone volumes in the same body region were segmented and further post-processed. Intra- and inter-reader reproducibility was assessed, with ICCs < 0.90 being considered non-reproducible. To account for imbalances in the dataset, data augmentation was performed to achieve improved class balance and to avoid model overfitting. The dataset was split into training, test, and validation set. After a multi-step dimension reduction process and feature selection process, the 11 most important and independent features were selected for statistical analyses.
A gradient-boosted tree was trained on the selected 11 radiomic features in order to classify patients' bones into bone metastasis and normal bone using the training dataset. This trained model achieved a classification accuracy of 0.85 (95% confidence interval [CI]: 0.76-0.92, p < .001) with 78% sensitivity and 93% specificity. The tuned model was applied on the original, non-augmented dataset resulting in a classification accuracy of 0.90 (95% CI: 0.82-0.98) with 91% sensitivity and 88% specificity.
Our proof-of-concept study indicates that radiomics may accurately differentiate unaffected bone from metastatic bone, being invisible by the human eye on CT.
• This proof-of-concept study showed that radiomics applied on CT images may accurately differentiate between bone metastases and metastatic-free bone in patients with prostate cancer. • Future promising applications include automatic bone segmentation, followed by a radiomics classifier, allowing for a screening-like approach in the detection of bone metastases.
European radiology. 2021 Sep 24 [Epub ahead of print]
Ricarda Hinzpeter, Livia Baumann, Roman Guggenberger, Martin Huellner, Hatem Alkadhi, Bettina Baessler
Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich, Raemistr. 100, CH-8091, Zurich, Switzerland. ., Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich, Raemistr. 100, CH-8091, Zurich, Switzerland., Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.